Applied dna reports second quarter fiscal 2023 financial results and provides corporate update

- lineardna ™ gaining momentum as a differentiated dna template for mrna production, company identifies early development-stage acquisition target to potentially expand commercial advantages - - balance of cy23 set up for multiple value inflection points - - conference call/webcast scheduled for today at 4:30 pm et - stony brook, ny / accesswire / may 11, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced consolidated financial results for the second quarter of fiscal 2023 ended march 31, 2023. commenting on the company's quarterly performance, dr. james a.
APDN Ratings Summary
APDN Quant Ranking